Question 1

What is ImmunityBio, Inc. Common Stock's WACC?

Accepted Answer

ImmunityBio, Inc. Common Stock (IBRX) has a Weighted Average Cost of Capital (WACC) of 11.98%. This is calculated using a Cost of Equity of 11.98% (via CAPM with a beta of 2.11) and a pre-tax Cost of Debt of 2.00%, with an equity weight of 99.99% in the capital structure.

Question 2

Is ImmunityBio, Inc. Common Stock's WACC high or low?

Accepted Answer

ImmunityBio, Inc. Common Stock's WACC of 11.98% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is ImmunityBio, Inc. Common Stock's WACC calculated?

Accepted Answer

ImmunityBio, Inc. Common Stock's WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 11.98% is derived from the CAPM model using a beta of 2.11. The pre-tax Cost of Debt (Rd) is 2.00%. The capital structure is 99.99% equity and 0.01% debt.

ImmunityBio, Inc. Common Stock (IBRX) — WACC 分析

WACC 构成

解读

ImmunityBio, Inc. Common Stock（IBRX）WACC：11.98%

WACC计算器

ImmunityBio, Inc. Common Stock（IBRX） WACC 解读

IBRX 公司分析

IBRX DCF 估值

继续做同行对比